🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

41 results for “ALX” Clear

  1. ALX1-11

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  2. ALX1-11 (drug)

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  3. ALXN 2040, ALXN 2040

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  4. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  5. ALXN1850 placebo product, ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  6. ALXN1850, ALXN1850 placebo product

    Alexion Europe SAS

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  7. ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  8. ALXN2060

    BridgeBio Oncology Therapeutics

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  9. ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)

    Alexion Europe SAS

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  10. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  11. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  12. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  13. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  14. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  15. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  16. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion Europe SAS

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  17. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)

    phase 3 small molecule active

    1 trial

  18. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Soliris 300 mg concentrate for solution for infusion, ALXN 2040

    Alexion Europe SAS

    Patients with Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  19. ALX-0600

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  20. ALX1-11 50 mcg

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  21. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  22. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  23. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  24. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources